Q-State Biosciences CEO and leadership

As Chief Executive Officer of Q-State Biosciences, Paul Medeiros is responsible for overseeing the company’s growth and sharpening its vision. He has nearly 25 years of global executive pharmaceutical experience with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. Prior to Q-State, Paul served as President and founding executive of Imbrium Therapeutics and directed the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment/accelerator firm Greenfield BioVentures. In addition to these roles, Paul has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Paul has also served on the boards of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. He received his AB with Honors from Brown University and his MBA from Columbia Business School

Graham Dempsey, Ph.D., leads Q-State’s research and development efforts. In this role, he oversees all internal development work and ensures successful execution of Q-State’s partnered programs with pharmaceutical companies and foundations. Graham began his scientific career at the University of Pennsylvania, developing novel single molecule methods for high sensitivity fluorescence measurements of molecular function. He then joined Harvard University where he developed a new super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM), allowing for multicolor, live-cell fluorescence imaging of biological samples with nanometer spatial resolution. The technique was commercialized by Nikon Instruments. Graham received a B.A. in Biochemistry and Physics from the University of Pennsylvania and a Ph.D. in Biophysics from Harvard University.

In his role as CFO, Chris Watt oversees Q-State’s accounting, treasury, reporting, and FP&A functions with over 30 years of financial and operational experience. Most recently, Chris served as Senior Vice President & Head of Finance at Tetraphase Pharmaceuticals where he helped raise over $150 million in capital, drove successful launch of the company’s first approved product, and helped lead the eventual sale of the company to La Jolla Pharmaceuticals. Prior to Tetraphase, he spent almost 11 years at Biogen, Inc. in various financial leadership roles, including Senior Director and Finance Lead for the company’s global commercial business. Chris has also worked in various financial and operational leadership roles at InterSystems Corporation, Putnam Investments, Procter & Gamble and Shawmut National Corporation. Chris holds a B.A. in economics and German from Colby College and an M.B.A. from the University of Michigan.

Drug Discovery Scientist with extensive experience in ion channel drug discovery. Led basic research teams at multiple discovery stages including target identification and validation, assay development, HTS setup, lead identification and optimization, and technology development. Experienced and productive at bench level through integration and management of drug discovery projects in multiple therapeutic areas.

As Chief Executive Officer of Q-State Biosciences, Paul Medeiros is responsible for overseeing the company’s growth and sharpening its vision. He has nearly 25 years of global executive pharmaceutical experience with an extensive track record of success in biopharma strategy, operations, R&D portfolio and corporate development. Prior to Q-State, Paul served as President and founding executive of Imbrium Therapeutics and directed the company’s business operations and R&D portfolio in the areas of pain and CNS therapeutics. He concurrently served as President of the associated investment/accelerator firm Greenfield BioVentures. In addition to these roles, Paul has fulfilled multiple corporate leadership positions within other biopharmaceutical companies including Mundipharma International in Cambridge UK, AVI BioPharma (now Sarepta Therapeutics), and Schering-Plough Pharmaceuticals. He began his pharma career as an MBA leadership trainee at Merck & Company. Paul has also served on the boards of directors of Praxis Precision Medicines, Kolltan Pharmaceuticals and EDO Pharmaceuticals GMBH. He received his AB with Honors from Brown University and his MBA from Columbia Business School